Abstract
The sigma-2 (σ2) receptor is proving to be an important protein in the field of cancer biology. The observations that σ2 receptors have a 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, and that σ2 receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important molecular target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and for the development of cancer chemotherapeutic agents. In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the molecular identity of the protein sequence of the σ2 receptor is currently not known. Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochemical analysis of the effect of σ2 selective ligands on cells growing under tissue culture conditions. This article provides a review of the development and use of σ2 receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.
Keywords: Sigma-2 receptors, cell proliferation, positron emission tomography
Central Nervous System Agents in Medicinal Chemistry
Title: Development of Molecular Probes for Imaging Sigma-2 Receptors in Vitro and in Vivo
Volume: 9 Issue: 3
Author(s): Robert Henry Mach and Kenneth Theodore Wheeler
Affiliation:
Keywords: Sigma-2 receptors, cell proliferation, positron emission tomography
Abstract: The sigma-2 (σ2) receptor is proving to be an important protein in the field of cancer biology. The observations that σ2 receptors have a 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, and that σ2 receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important molecular target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and for the development of cancer chemotherapeutic agents. In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the molecular identity of the protein sequence of the σ2 receptor is currently not known. Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochemical analysis of the effect of σ2 selective ligands on cells growing under tissue culture conditions. This article provides a review of the development and use of σ2 receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.
Export Options
About this article
Cite this article as:
Mach Henry Robert and Wheeler Theodore Kenneth, Development of Molecular Probes for Imaging Sigma-2 Receptors in Vitro and in Vivo, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030230
DOI https://dx.doi.org/10.2174/1871524910909030230 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Mechanistic Insights into Mode of Action of a Potent Natural Antagonist of Orexin Receptor-1 by Means of High Throughput Screening and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
Current Alzheimer Research Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study
Current Alzheimer Research Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Effect of Systemic Inflammation on the Function of Insulin and Glucose Metabolism in Rheumatoid Arthritis
Current Diabetes Reviews Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons
Current Alzheimer Research Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics
Current Alzheimer Research Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Next Steps in Alzheimers Disease Research: Interaction between Epidemiology and Basic Science
Current Alzheimer Research Environmental Tobacco Smoke Exposure and Airway Hyperresponsiveness
Inflammation & Allergy - Drug Targets (Discontinued) The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design 1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review
Central Nervous System Agents in Medicinal Chemistry Activation of the Innate Immune System in Atherosclerotic Disease
Current Pharmaceutical Design Development, Validation and Application of an LC-MS/MS Bioanalytical Method for the Quantification of GF449, A Novel 5-HT<sub>1A</sub> Agonist, in Rat Plasma and Brain
Medicinal Chemistry A Novel Neuroimaging Model to Predict Early Neurological Deterioration After Acute Ischemic Stroke
Current Neurovascular Research Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology